D-0012-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0012-2021 was initiated by Teva Pharmaceuticals USA on Aug 24, 2020 and is designated Class II. Reason for recall: CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits. The recall status is terminated (terminated Dec 16, 2021). Affected quantity: 103,940 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 16, 2020
Initiation Date
Aug 24, 2020
Termination Date
Dec 16, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
103,940 bottles

Product description

Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Reason for recall

CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.

Distribution pattern

Nationwide in the U.S. and Puerto Rico.

Code information

Lot #s: a) 30309820A, Exp. 08/2020; 30310000B, 30310001B, Exp. 10/2020; 30310096A Exp. 01/2021; 30310228A, Exp. 03/2021; 30310313A, Exp. 06/2021; b) 30309861A, Exp. 08/2020; 30310335A, Exp. 06/2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0012-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0012-2021. Report a data issue: hello@regdatalab.com.